Sulodexide. Nephroprotective properties and horizons for use in nephrology
https://doi.org/10.21518/2079-701X-2015-7-68-71
Abstract
Sulodexide belongs to the class of glycosaminoglycans (GAGs) or mucopolysaccharides. Found in mammalian tissuesm, GAGs regulate the activity of a wide range of proteins (including chemokines, cytokines, growth factors, enzymes, morphogens, and adhesion molecules). GAGs are large, linear, frequently sulfated, negatively charged polysaccharides with a molecular weight ranging 1-2,000 kDa. They are organized as repetitions of disaccharide units of an uronic acid (D-glucuronic acid or L-iduronic acid) and an acetylated amino sugar (N-acetylgalactosamine or N-acetylglucosamine) either sulfated or non-sulfated. [5] The position of sulfation of GAGs is widely variable depending on their cell and tissue localization. GAGs exist both as part of proteoglycans and as free chains. Non-sulfated GAGs include hyaluronic acid and sulfated GAGs include chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, and heparan sulfate.
About the Author
M. M. Batyushin
Rostov State Medical University, Russia's Ministry of Health
Russian Federation
Russian Federation
References
1. Батюшин М.М., Галушкин А.А., Литвинов А.С. и соавт. Место сулодексида в ренопротективной терапии больных с хронической болезнью почек. Медицинский вестник Юга России. 2012; 1: 72-73.
2. Батюшин М.М., Галушкин А.А., Асрумян Э.Г. и соавт. Сулодексид - новые перспективы в нефропротективной терапии. Клиническая нефрология. 2012; 3: 56-61.
3. Батюшин М.М., Пасечник Д.Г. Выявление виментина, панцитокератина, гладкомышеч-ного актина, е-катгерина и антител к CD-10 -маркеров эпителиально-мезенхимального перехода при хроническом гломерулонефрите. Нефрология. 2014; 5: 52-58.
4. ALicic RZ, TuttLe KR. Novel Therapies for Diabetic Kidney Disease. Advances in Chronic Kidney Disease. 2014; 21(2): 121-133.
5. Coccheri S, ManneLLo F. Development and use of suLodexide in vascuLar diseases: impLications for treatment. Drug Design, Development and Therapy. 2014; 8: 49-65.
6. Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y et aL. Loss of heparin suLfate gLycosaminogLy-can assembLy in podocytes does not Lead to proteinuria. Kidney Int. 2008; 74(3): 289-299.
7. Wijnhoven TJ, Lensen JF, Rops AL et aL. Anti-proteinuric effects of gLycosaminogLycan-based drugs. Curr Opin Mol Ther. 2007; 9(4): 364-377.
8. CeLie JW, Reijmers RM, SLot EM et aL. TubuLointerstitiaL heparan suLfate proteogLycan changes in human renaL diseases correLate with Leukocyte infLux and proteinuria. Am J Physiol Renal Physiol. 2008; 294(1): 253-263.
9. Benck U, HaeckeL S, CLorius JH, van der Woude FJ. Proteinuria- Lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aLdosterone system. Clin J Am Soc Nephrol. 2007; 2(1): 58-67.
10. Ruggeri A, Guizzardi S, Franchi M et aL. Pharmacokinetics and distribution of a fLuores-ceinated gLycosaminogLycan, suLodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35(10): 1517-1519.
11. Lewis EJ, Xu X. AbnormaL gLomeruLar permeabiLity characteristics in diabetic nephropathy: impLications for the therapeutic use of Low-moLecuLar weight heparin. Diabetes Care. 2008; 31 SuppL 2: S202-S207.
12. Gouverneur M, Broekhuizen L, Meuwese M et aL. SuLfated gLycosaminogLycans restore gLyco-caLyx barrier properties of cuLtured endotheLiaL ceLLs in hypergLycemia. FASEB J. 2008; 22: Lb83.
13. Karon J, Potubinska A, Antoniewicz AA. et aL. Anti-infLammatory effect of suLodexide during acute peritonitis in rats. Blood Purif. 2007; 25(5-6): 510-514.
14. Ciszewicz M, PoLubinska A, Antoniewicz A. et aL. SuLodexide suppresses infLammation in human endotheLiaL ceLLs and prevents gLucose cytotox-icity. Transl Res. 2009; 153(3): 118-123.
15. Shestakova M.V., Chugunova L.A., Vorontsov A.V., Dedov I.I. The efficacy of suLodexide - a Low-moLecuLar heparin - in the therapy of diabetic nephropathy. Ter Arkh. 1997; 69(6): 34-37.
16. SzeLachowska M., PopLawska A., TopoLska J. et aL. A piLot study of the effect of the gLycosami-nogLycan suLodexide on microaLbuminuria in type I diabetic patients. Curr Med Res Opin. 1997; 13(9): 539-545.
17. Sorrenti G., GrimaLdi M., Canova N. et aL. GLycosaminogLycans as a possibLe tooL for micro- and macroaLbuminuria in diabetic patients. A piLot study. J Int Med Res. 1997; 25(2): 81-86.
18. SoLini A., Vergnani L., Ricci F., CrepaLdi G. GLycosaminogLycans deLay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5): 819-823.
19. Dedov I., Shestakova M., Vorontzov A., PaLazzini E. A randomized, controLLed study of suLodexide therapy for the treatment of diabetic nephrop-athy. NephroL DiaL TranspLant. 1997; 12(11): 2295-2300.
20. Gambaro G., KinaLska I., Oksa A. et aL. OraL suLo-dexide reduces aLbuminuria in microaLbuminu-ric and macroaLbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized triaL. J Am Soc NephroL. 2002; 13: 1615-1625.
21. Heerspink H.L., Greene T., Lewis J.B. et aL. CoLLaborative Study Group. Effects of suLodex-ide in patients with type 2 diabetes and persistent aLbuminuria. NephroL DiaL TranspLant. 2008; 23(6): 1946-1954.
22. Achour A., Kacem M., Dibej K. et aL. One year course of oraL suLodexide in the management of diabetic nephropathy. J NephroL. 2005; 18(5): 568-574.
23. SuLikowska B., OLejniczak H., Muszynska M. et aL. Effect of suLodexide on aLbuminuria, NAG excretion and gLomeruLar fiLtration response to dopamine in diabetic patients. Am J NephroL. 2006; 26(6): 621-628.
Review
For citations:
Batyushin MM. Sulodexide. Nephroprotective properties and horizons for use in nephrology. Meditsinskiy sovet = Medical Council. 2015;(7):68-71. (In Russ.) https://doi.org/10.21518/2079-701X-2015-7-68-71
Views:
406
Email this article 